RESEARCH REPORT
Merck & Company, Inc.
MRK
$149.52
As of 2026-11-01
Research note — 2026-11-01. Educational analysis, not financial advice.
The one-line version
Merck & Company, Inc. trades near $149.52 on a trailing multiple of about 151.0x versus its own 5-year median near 104.2x, against contested Street targets and the usual concentration and execution risks. That's the tension. Everything below is the detail.
That's the tension. Everything below is the detail.
1. What you're paying
| Now | Its own 5-year median | Gap | |
|---|---|---|---|
| P/E (trailing) | ~151.0 | ~104.2 | +45% |
| P/E (forward) | ~16.4 | — | — |
| EPS (TTM) | 0.99 | — | — |
| Gross margin | 76.9% | — | — |
What that means in plain terms: the gap versus the company's own history is the growth or durability the market is already pricing. It is not automatically wrong — it is the bet.
Fair-value anchors on file:
- 5-year median P/E multiple: $103.13 — Applies the 5-year median multiple (104.2x) to trailing EPS.
- Street mean target: $159.83 — Average published analyst target.
- Street target midpoint: $145.50 — Midpoint of $105.00–$186.00 published range.
Street targets run from $105.00 to $186.00. A wide spread means the name is contested, not consensus.
2. What the bulls are counting on
- MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds
- How market participants Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine Data
- Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
3. What the bears see
- Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit Squeeze
- Why Merck Stock Flew Higher on Friday
- JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $175
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
4. What would have to be true
For the stock to justify ~151.0x rather than its 5-year ~104.2x, roughly all of the following need to neutral:
- Growth or margin durability shows up in the next several reports, not just in narrative.
- Key revenue concentrations survive competitive and regulatory pressure.
- Execution on the current product or services cycle stays on schedule.
- The Street target range compresses as results clarify the contested assumptions.
Ask yourself honestly: how many of those would you bet on individually? Multiply your answers together.
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
5. What to watch next
- Next earnings date: 1793277000
- Trailing and forward multiples versus the company's own history
- Segment growth rates in the next 10-Q / earnings release
- Material Form 4 and 13F changes
- Whether the Street high-to-low target spread narrows or widens
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
6. What this note does not do
It doesn't tell you to buy or sell. It won't, ever.
You have the valuation in context, the strongest version of both cases, and the specific assumptions the current price depends on. What you do with that depends on your time horizon, your existing exposure, your risk tolerance, and what else you could do with the money — none of which we know.
If you want someone to tell you what to do, you want a licensed financial adviser, and that is a genuinely reasonable thing to want.
Educational and informational purposes only. Not investment advice and not a recommendation to buy or sell any security. GetStockReport is not a registered investment adviser. Figures are as of 2026-11-01 and go stale quickly — verify against primary sources before acting. All investments carry risk including loss of principal. Past performance does not guarantee future results.
8. Analyst ratings & targets
No recent activity
Analyst opinions change frequently. Past upgrades do not predict future returns.
9. Important news
Nov 6, 2026|Moderna Hits Five-Year High On Sales Beat; But The Real Story Is Still Its Cancer Vaccine(Yahoo)
Moderna stock surged to a five-year high Friday on the back of its Street-walloping vaccine sales and guidance hike for the year.
Nov 6, 2026|Halozyme Therapeutics (HALO) Following Record Results And Higher Guidance Is The Stock Still Undervalued(Yahoo)
Halozyme Therapeutics (HALO) just posted third quarter 2026 results that featured record revenue of US$492.97 million and net income of US$247.05 million, along with higher full year guidance and ongoing Merck litigation. The latest numbers come after a powerful run in Halozyme Therapeutics’ shares, with a year-to-date share price return of 74.88% and a 1-year total shareholder return of 80.19%. This performance comes even though the stock has slipped 5.66% over the last day and 6.07% over...
Nov 6, 2026|Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?(Yahoo)
MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth.
Nov 6, 2026|Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher(Yahoo)
Moderna flipped a forecasted loss into a profit, yet part of the first pop has already faded while bigger rivals barely budge. What is holding back the rally, and which open question could decide the stock's next move?
Nov 6, 2026|The One Thing To Settle Before Buying AbbVie Stock(Yahoo)
For questions about this article or underlying research, email help@trefis.com.
News headlines are reported as-is. Verify important claims with original sources.
10. Insider Form 4 activity
| Date | Executive | Action | Shares | Value |
|---|---|---|---|---|
| Nov 1, 2026 | DIAZ PAUL J | Sell | 613.073 | $91,666.67 |
Form 4 filings are routine transactions. Scheduled sales (10b5-1 plans) are normal and not signals.
11. Institutional 13F holdings
| Fund | Shares | Position | Change |
|---|---|---|---|
| Vanguard Group | 229,006,389 | $24.1B | — |
| State Street | 120,413,256 | $15.6B | — |
| BlackRock | 75,200 | $9.3B | — |
| BlackRock Institutional Trust | 12,473,411 | $734.3M | — |
These are 45-day lagged filings (SEC requirement). Position changes happened in the past.
12. Earnings this week
No recent activity
Earnings dates are estimates and may shift. EPS estimates are consensus, not predictions.